
INmune Bio, Inc. – NASDAQ:INMB
INmune Bio stock price today
INmune Bio stock price monthly change
INmune Bio stock price quarterly change
INmune Bio stock price yearly change
INmune Bio key metrics
Market Cap | 98.88M |
Enterprise value | 101.79M |
P/E | -5 |
EV/Sales | 272.17 |
EV/EBITDA | -3.72 |
Price/Sales | 370.68 |
Price/Book | 2.30 |
PEG ratio | -0.31 |
EPS | -1.92 |
Revenue | 131K |
EBITDA | -34.33M |
Income | -34.49M |
Revenue Q/Q | -63.15% |
Revenue Y/Y | -47.38% |
Profit margin | -7299.2% |
Oper. margin | -6938.77% |
Gross margin | 0% |
EBIT margin | -6938.77% |
EBITDA margin | -26209.92% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeINmune Bio stock price history
INmune Bio stock forecast
INmune Bio financial statements
Jun 2023 | 46K | -6.50M | -14132.61% |
---|---|---|---|
Sep 2023 | 43K | -8.56M | -19913.95% |
Dec 2023 | 28K | -8.40M | -30028.57% |
Mar 2024 | 14K | -11.02M | -78750% |
2025 | 29K | -48.46M | -167127.59% |
---|---|---|---|
2026 | 29.5K | -49.05M | -166274.58% |
2027 | 82.70M | 24.45M | 29.57% |
2028 | 146.16M | 73.09M | 50.01% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 69720000 | 19.06M | 27.35% |
---|---|---|---|
Sep 2023 | 62698000 | 17.96M | 28.65% |
Dec 2023 | 57001000 | 18.86M | 33.09% |
Mar 2024 | 46833000 | 17.81M | 38.03% |
Jun 2023 | -3.17M | 0 | 0 |
---|---|---|---|
Sep 2023 | -4.26M | -2.55M | -1.72M |
Dec 2023 | -3.40M | 2.55M | -2.5M |
Mar 2024 | -7.47M | 0 | -2.5M |
INmune Bio alternative data
Aug 2023 | 10 |
---|---|
Sep 2023 | 10 |
Oct 2023 | 10 |
Nov 2023 | 10 |
Dec 2023 | 10 |
Jan 2024 | 10 |
Feb 2024 | 10 |
Mar 2024 | 10 |
Apr 2024 | 10 |
May 2024 | 11 |
Jun 2024 | 11 |
Jul 2024 | 11 |
INmune Bio other data
Period | Buy | Sel |
---|---|---|
Nov 2023 | 7000 | 0 |
Apr 2024 | 160164 | 0 |
Jun 2024 | 5000 | 0 |
Sep 2024 | 56140 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | MOSS DAVID J 10 percent owner, officer: Chie.. | Common Stock | 10,000 | $5.29 | $52,870 | ||
Purchase | TESI RAYMOND JOSEPH director, 10 perc.. | Common Stock | 15,380 | $6.38 | $98,048 | ||
Purchase | TESI RAYMOND JOSEPH director, 10 perc.. | Common Stock Warrants (right to buy) | 15,380 | $6.4 | $98,432 | ||
Purchase | MOSS DAVID J 10 percent owner, officer: Chie.. | Common Stock | 7,690 | $6.38 | $49,024 | ||
Purchase | MOSS DAVID J 10 percent owner, officer: Chie.. | Common Stock Warrants (right to buy) | 7,690 | $6.4 | $49,216 | ||
Purchase | JUDA SCOTT director | Common Stock | 5,000 | $7.27 | $36,350 | ||
Purchase | MOSS DAVID J 10 percent owner, officer: CFO,.. | Common Stock | 18,028 | $8.32 | $149,993 | ||
Purchase | MOSS DAVID J 10 percent owner, officer: CFO,.. | Common Stock Warrants (right to buy) | 18,028 | $9.15 | $164,992 | ||
Purchase | TESI RAYMOND JOSEPH director, 10 perc.. | Common Stock | 18,028 | $8.32 | $149,993 | ||
Purchase | TESI RAYMOND JOSEPH director, 10 perc.. | Common Stock Warrants (right to buy) | 18,028 | $9.15 | $164,992 |
Patent |
---|
Application Filling date: 13 May 2020 Issue date: 4 Aug 2022 |
Application Filling date: 27 Sep 2018 Issue date: 17 Sep 2020 |
Quarter | Transcript |
---|---|
Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. David J. Moss M.B.A. (1970) Chief Financial Officer, Treasurer & Sec. | $300,000 |
Dr. Raymond Joseph Tesi (1956) Co-Founder, Pres, Chief Executive Officer, Chief Medical Officer & Chairman | $300,000 |
Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR (1963) Chief Scientific Officer & Chief Manufacturing Officer | $138,200 |
INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's
INmune Bio: Finding Pay Dirt In Alzheimer's?
INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity
Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients
NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025
INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers
INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro
INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection
-
What's the price of INmune Bio stock today?
One share of INmune Bio stock can currently be purchased for approximately $2.41.
-
When is INmune Bio's next earnings date?
Unfortunately, INmune Bio's (INMB) next earnings date is currently unknown.
-
Does INmune Bio pay dividends?
No, INmune Bio does not pay dividends.
-
How much money does INmune Bio make?
INmune Bio has a market capitalization of 98.88M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 58.56% to 155K US dollars.
-
What is INmune Bio's stock symbol?
INmune Bio, Inc. is traded on the NASDAQ under the ticker symbol "INMB".
-
What is INmune Bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of INmune Bio?
Shares of INmune Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are INmune Bio's key executives?
INmune Bio's management team includes the following people:
- Mr. David J. Moss M.B.A. Chief Financial Officer, Treasurer & Sec.(age: 55, pay: $300,000)
- Dr. Raymond Joseph Tesi Co-Founder, Pres, Chief Executive Officer, Chief Medical Officer & Chairman(age: 69, pay: $300,000)
- Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR Chief Scientific Officer & Chief Manufacturing Officer(age: 62, pay: $138,200)
-
Is INmune Bio founder-led company?
Yes, INmune Bio is a company led by its founder Dr. Raymond Joseph Tesi.
-
How many employees does INmune Bio have?
As Jul 2024, INmune Bio employs 11 workers, which is 10% more then previous quarter.
-
When INmune Bio went public?
INmune Bio, Inc. is publicly traded company for more then 6 years since IPO on 4 Feb 2019.
-
What is INmune Bio's official website?
The official website for INmune Bio is inmunebio.com.
-
Where are INmune Bio's headquarters?
INmune Bio is headquartered at 225 NE Mizner Boulevard, Boca Raton, FL.
-
How can i contact INmune Bio?
INmune Bio's mailing address is 225 NE Mizner Boulevard, Boca Raton, FL and company can be reached via phone at 858 964 3720.
INmune Bio company profile:

INmune Bio, Inc.
inmunebio.comNASDAQ
11
Biotechnology
Healthcare
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Boca Raton, FL 33432
CIK: 0001711754
ISIN: US45782T1051
CUSIP: 45782T105